Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients
暂无分享,去创建一个
[1] Gary H Lyman,et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.
[2] Samuel Z Goldhaber,et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study , 2008, The Lancet.
[3] J. Jansson,et al. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta‐analysis , 2007, Journal of internal medicine.
[4] J. Douketis,et al. The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism , 2007, Annals of Internal Medicine.
[5] Gary H Lyman,et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Nokes,et al. Derivation and Validation of a Prediction Tool for Venous Thromboembolism: A VERITY Registry Study. , 2007 .
[7] J. Donovan,et al. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. , 2007, Clinical therapeutics.
[8] H. Büller,et al. Prevention of catheter‐related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo‐controlled study , 2007, Journal of thrombosis and haemostasis : JTH.
[9] A. Turpie,et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. , 2007, Chest.
[10] R. Milani,et al. Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients , 2007, Vascular health and risk management.
[11] H. Krum,et al. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. , 2007, Archives of internal medicine.
[12] R. Goldberg,et al. Venous thromboembolism in the outpatient setting. , 2007, Archives of internal medicine.
[13] J. Hirsh,et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery , 2007, Journal of thrombosis and haemostasis : JTH.
[14] A. Tefferi,et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.
[15] A. Tefferi,et al. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. , 2007, Seminars in thrombosis and hemostasis.
[16] J. Hanley,et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. , 2007, The Lancet. Oncology.
[17] C. Kase,et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison , 2007, The Lancet.
[18] C. Francis. Prophylaxis for Thromboembolism in Hospitalized Medical Patients , 2007 .
[19] M. Rodger,et al. The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials , 2007, Journal of thrombosis and haemostasis : JTH.
[20] P. Romundstad,et al. Incidence and mortality of venous thrombosis: a population‐based study , 2007, Journal of thrombosis and haemostasis : JTH.
[21] A. Khorana,et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.
[22] J. Douketis,et al. Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients , 2007, Annals of Internal Medicine.
[23] A. Shorr,et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. , 2007, Chest.
[24] G. Tiscia,et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.
[25] V. Hach-Wunderle,et al. An Evaluation of Venous Thromboembolic Risk in Acutely Ill Medical Patients Immobilized at Home: The AT-HOME Study , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[26] H. Chew,et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] A. Panju,et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. , 2007, Thrombosis research.
[28] A. Encke,et al. [Preventing venous thromboembolism]. , 2007, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[29] P. Novotny,et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. , 2007, Mayo Clinic proceedings.
[30] P. Mannucci,et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis , 2006, Hepatology.
[31] D. Gaitini,et al. Prevalence of Upper Extremity Deep Venous Thrombosis Diagnosed by Color Doppler Duplex Sonography in Cancer Patients With Central Venous Catheters , 2006, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[32] M. Samama,et al. An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients , 2006, Thrombosis journal.
[33] M. Levine,et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] H. Chew,et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.
[35] G. Steger,et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] M. Prins,et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.
[37] J. Labarère,et al. Determining Indications for Care Common to Competing Guidelines by Using Classification Tree Analysis: Application to the Prevention of Venous Thromboembolism in Medical Inpatients , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[38] P. Prandoni,et al. Cancer and venous thromboembolism. , 1996, Seminars in thrombosis and hemostasis.
[39] G. Geroulakos,et al. Prevention and Treatment of Venous Thromboembolism , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[40] P. Stein,et al. Incidence of venous thromboembolism in patients hospitalized with cancer. , 2006, The American journal of medicine.
[41] J. Kahan,et al. An electronic tool for venous thromboembolism prevention in medical and surgical patients. , 2006, Haematologica.
[42] A. Khorana,et al. Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study , 2005, Cancer.
[43] A. Turpie,et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients , 2005, Thrombosis and Haemostasis.
[44] S. Yale,et al. Risk assessment model for venothromboembolism in post-hospitalized patients. , 2005, International angiology : a journal of the International Union of Angiology.
[45] J. Olsen,et al. The risk of a second cancer after hospitalisation for venous thromboembolism , 2005, British Journal of Cancer.
[46] H. Chew,et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. , 2005, Archives of internal medicine.
[47] I. Mahé,et al. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study , 2005, European Journal of Clinical Pharmacology.
[48] D. Anderson,et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Armando Santoro,et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] P. Langhorne,et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review , 2005, Thrombosis and Haemostasis.
[51] J. Bergmann,et al. Venous thromboembolism in the medically ill patient: a call to action , 2005, International journal of clinical practice.
[52] D. Hayoz,et al. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement , 2005, Journal of internal medicine.
[53] Susanne M. Smorenburg,et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] M. Prins,et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] E. Medico,et al. The MET oncogene drives a genetic programme linking cancer to haemostasis , 2005, Nature.
[56] F. Rosendaal,et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. , 2005, JAMA.
[57] Marilyn D Paterno,et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. , 2005, The New England journal of medicine.
[58] A. Leizorovicz,et al. Preventing Venous Thromboembolism in Medical Patients , 2004, Circulation.
[59] S. Humphries,et al. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway , 2004, Journal of thrombosis and haemostasis : JTH.
[60] M. Cushman,et al. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score , 2004, Journal of thrombosis and haemostasis : JTH.
[61] Clifford W Colwell,et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[62] S. Goldhaber,et al. Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.
[63] S. Deitcher,et al. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma , 2004, Cancer.
[64] A. Unal,et al. A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer , 2004, Journal of thrombosis and haemostasis : JTH.
[65] M. Müller,et al. Complicated Case of Left Ventricular Echinococcosis , 2004 .
[66] J. Murchison,et al. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study , 2004, British Journal of Cancer.
[67] T. M. Norris,et al. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin , 2004, Thrombosis and Haemostasis.
[68] Michael Thomas,et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] A. Turpie,et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. , 2004, Archives of internal medicine.
[70] P. Lønning,et al. Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.
[71] S. Goldhaber,et al. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. , 2004, The American journal of cardiology.
[72] G. Agnelli,et al. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] R. Wolff,et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. , 2003, The oncologist.
[74] C. Witt,et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. , 2003, American heart journal.
[75] J. Heit,et al. Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.
[76] L. Melton,et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.
[77] P. Reitsma,et al. Genetic risk factors for venous thrombosis. , 2000, Molecular genetics and metabolism.
[78] S. Schulman,et al. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. , 2000, The New England journal of medicine.
[79] E. Oger. Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.
[80] W M O'Fallon,et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.
[81] Lain,et al. A COMPARISON OF ENOXAPARIN WITH PLACEBO FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS , 2000 .
[82] M. Cucherat,et al. Prevention of Venous Thromboembolism in Internal Medicine with Unfractionated or Low-molecular-weight Heparins: A Meta-analysis of Randomised Clinical Trials , 2000, Thrombosis and Haemostasis.
[83] A. Turpie,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.
[84] A A Rimm,et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.
[85] J. Olsen,et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.
[86] L. Welin,et al. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. , 1997, Archives of internal medicine.
[87] F. Rosendaal. Risk factors for venous thrombosis: prevalence, risk, and interaction. , 1997, Seminars in hematology.
[88] B. Zee,et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] J. Bergmann,et al. Heparin prophylaxis in bedridden patients , 1996, The Lancet.
[90] B. Gårdlund,et al. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases , 1996, The Lancet.
[91] R. Rosell,et al. Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin) , 1996, Thrombosis and Haemostasis.
[92] B. Gärdlund. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. , 1996, Lancet.
[93] D. Hosmer,et al. The prevalence of risk factors for venous thromboembolism among hospital patients. , 1992, Archives of internal medicine.
[94] B. Lindblad,et al. A prospective study of the incidence of deep‐vein thrombosis within a defined urban population , 1992, Journal of internal medicine.
[95] Venous thromboembolism and cancer. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[96] P. Benotti,et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.
[97] B. Modan,et al. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. , 1982, Annals of internal medicine.
[98] E. Pollak,et al. Fatal Pulmonary Embolism in Cancer Patients: Is Heparin Prophylaxis Justified , 1980, Southern medical journal.
[99] Small subcutaneous doses of heparin in prevention of venous thrombosis. , 1973, The New England journal of medicine.